Riskpilot← Back to searchSign inGet full accessEndoskopi i Skåne AB
ABActiveOrg 5569169005Prästgatan 24Medical specialists activities · NACE 8622Est. 20121 employees
Revenue 2025
SEK 3,7M
-5% vs 2024
EBITDA margin
74.9%
+2% vs 2024
Equity ratio
77.2%
Financial strength
Net profit 2025
SEK 3,9M
+92% vs 2024
| Revenue | SEK 3,7M | -5% |
| EBITDA | SEK 2,8M | +2% |
| Net profit | SEK 3,9M | +92% |
| Total assets | SEK 14,2M | +39% |
| Equity | SEK 10,9M | +50% |
| Employees | 1 | — |
Legal name
Endoskopi i Skåne AB
Org number
5569169005
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
21 december 2012
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Föremålet för bolagets verksamhet är privat sjukvårdsverksamhet, försäljning av läkemedel och medicinsk utrustning, handel med värdepapper för egen räkning och därmed förenlig verksamhet.
Address
Prästgatan 24
Email
andre@azaborowski.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 4 284 | 5 003 | 4 327 | 3 931 | 3 732 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 3 816 | 4 024 | 3 208 | 2 750 | 2 795 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 3 816 | 4 024 | 3 208 | 2 750 | 2 795 |
| Net financials | — | 10 | 131 | −412 | 2 041 |
| Profit before tax | 2 866 | 3 074 | 2 567 | 2 666 | 4 857 |
| Tax | −592 | −635 | −538 | −633 | −951 |
| Net profit | 2 274 | 2 439 | 2 029 | 2 033 | 3 906 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 4 384 | 6 984 | 9 185 | 10 235 | 14 181 |
| Equity | 2 613 | 3 652 | 5 681 | 7 283 | 10 949 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 675 | 1 276 | 676 | 142 | 441 |
| Total debt | 675 | 1 276 | 676 | 142 | 441 |
EBITDA margin
74.9%
This company
15.8%
Market median
+374% vs market
20212025
Equity ratio
77.2%
This company
38.2%
Market median
+102% vs market
20212025
Return on equity
35.7%
This company
18.4%
Market median
+94% vs market
20212025
Net profit margin
104.7%
This company
8.1%
Market median
+1193% vs market
20212025
Asset turnover
0.26×
This company
1.12×
Market median
-77% vs market
20212025
Debt / equity
0.30×
This company
0.62×
Market median
+52% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
GÅ | Audit | 2022 |
MT | Audit | 2026 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Endoskopi i Skåne AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Glen Åke Krister Nilsson | Audit | 0 companies |
| Marie Therese Jägenstedt | Audit | 0 companies |
| Nicole Julia Zaborowski | Deputy Board Member | 0 companies |
| Andrzej Zaborowski | Board of Directors | 0 companies |